Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 18
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/29/2008
 
First Published:
12/8/2006
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV, Phase III
Treatment
Active
21 and under
Other
GPOH-NB2004
EU-20661, NCT00410631
Last Modified:
9/19/2008
 
First Published:
11/1/2001
2.
Phase III Randomized Study of Adjuvant Isotretinoin With or Without Monoclonal Antibody Ch14.18, Interleukin-2, and Sargramostim (GM-CSF) in Patients With Neuroblastoma Who Have Completed Myeloablative Therapy and Autologous Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
30 and under at diagnosis
NCI
COG-ANBL0032
COG-P9842, NCT00026312
Last Modified:
1/2/2008
 
First Published:
2/1/2002
3.
Phase III Randomized Study of Induction Chemotherapy With or Without Filgrastim (G-CSF) Followed By Surgery, Myeloablative Therapy, and Radiotherapy With Isotretinoin With or Without Monoclonal Antibody Ch14.18 in Patients With High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
1 to 20 at diagnosis
Other
SIOP-EUROPE-HR-NBL-1
ESIOP, EU-20148, NCT00030719
Last Modified:
9/19/2008
 
First Published:
10/21/2006
4.
Phase III Randomized Study of Standard Chemoradiotherapy With or Without Carboplatin Followed by Standard Maintenance Therapy With or Without Isotretinoin and Continuation Therapy With Isotretinoin Versus No Continuation Therapy in Pediatric Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
3 to 21
NCI
COG-ACNS0332
ACNS0332, NCT00392327
Last Modified:
9/18/2008
 
First Published:
7/6/2007
5.
Phase III Study of Response- and Biology-Based Combination Chemotherapy and Surgery With or Without Isotretinoin in Young Patients With Intermediate-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
12 and under
NCI
COG-ANBL0531
ANBL0531, NCT00499616
Last Modified:
9/19/2008
 
First Published:
12/3/2007
6.
Phase III Randomized Study of Single Versus Tandem Myeloablative Consolidation Therapy Followed by Peripheral Blood Stem Cell Transplantation in Young Patients With High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
30 and under
NCI
COG-ANBL0532
ANBL0532, NCT00567567
Last Modified:
8/23/2006
 
First Published:
5/5/2006
7.
Phase I/II Study of Vorinostat (SAHA) in Combination With Isotretinoin in Patients With Advanced Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
21 and over
NCI
NYWCCC-0511008257
6896, NCI-6896, NCT00324740
8.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
2006-0709
NCT00555399
Last Modified:
6/2/2008
 
First Published:
2/5/2008
9.
Phase I/II Study of Cytoreduction Therapy Comprising High-Dose Cytarabine and Mitoxantrone Hydrochloride in Patients With Juvenile Myelomonocytic Leukemia Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Residual Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Juvenile
NCI
UMN-1999LS032
UMN-1999LS032, UMN-MT1999-08, NCT00609739
10.
A Phase I/Ii Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
Under 21
Other
22053
NCT00703222
Select All on One Page
1
2
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute